By Bob Rochelle (Cleveland Diagnostics)2024-02-06T11:36:56
While blood tests measuring prostate-specific antigen (PSA) levels have been a primary screening tool, their limitations in specificity have led to challenges such as overdiagnosis and overtreatment. Cleveland Diagnostics is pioneering an alternative approach with the IsoPSA test, focusing on assessing the structure of the PSA protein rather than its ...
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-20T13:00:00Z
2026-11-20T08:00:00Z
Contributor Dr Rahul Gupta, By Drug Target Review
2026-11-18T11:12:00Z
2024-05-10T11:23:31
Sponsored by BellBrook Labs
2025-05-08T09:00:00
Contributor Ning Ren
2024-01-10T08:23:16
Sponsored by BellBrook Labs
2024-02-01T12:06:43
Sponsored by Leica Microsystems
2026-07-01T06:30:00
Sponsored by BPS Bioscience, By Dr Veronique Baron
2025-04-02T14:00:00
Sponsored by Eurofins Discovery
Site powered by Webvision Cloud